Oregon-based bioscience company joins more than 400 science and business leaders in the protein and antibody industry for a two-day conference in April.
PORTLAND, Ore. – AbSci, an Oregon-based bioscience company, is headed to London next week to present its novel proprietary expression system at the 7th Annual Proteins and Antibodies Congress, a conference drawing leading scientific experts and companies from around the world on April 3rd and 4th. AbSci will be the only vendor company at the event with headquarters in the Pacific Northwest.
AbSci will showcase SoluPro™, its bioengineered E. coli expression system, to more than 400 attendees from the proteins and antibodies field. SoluPro™ expedites the drug discovery process while reducing production time and cost, and allows the scalable production of soluble recombinant antibodies, enzymes and other proteins without altering their characteristics.
“As AbSci enters new markets, it’s crucial for us to make strong connections with the leaders shaping the proteins and antibodies business,” said AbSci CEO Sean McClain. “We’re not only looking to reach the next level of business growth, we’re also looking to be at the forefront of the protein expression industry on a global scale.”
Attendees representing leading pharmaceutical, biopharmaceutical and biotechnology companies and institutions will convene at the conference to discuss the latest discovery and development platforms for next generation antibodies, the use of engineered antibodies in cancer therapy, and the latest insights into targeting difficult receptors and increasing clinical success rate.
McClain will join AbSci co-founder and scientific advisor Mark Valasek and scientist Phil Barish at the conference, where together they will meet with conference delegates to discuss how SoluPro™ can advance products in the biopharmaceutical pipeline.
This event follows a series of milestones for AbSci, which recently announced a 300-percent increase in its workforce since joining the OTRADI Bioscience Incubator in June 2013. The conference marks the start of the company’s latest effort to secure global partnerships and business.
Established in 2011, AbSci is committed to enhancing global health by reducing biotherapeutic costs and advancing clean energy technologies. As part of this aim, AbSci developed SoluPro™, a bioengineered E. coli expression system that expedites the drug discovery process while reducing production time and cost, and allows the scalable production of soluble recombinant antibodies, enzymes and other proteins without altering their characteristics. AbSci is headquartered at the OTRADI Bioscience Incubator in Portland, Ore., one of the United States’ fastest growing bioscience clusters. http://www.abscibio.com.